ReachMD CME

CME credits: 0.25 Valid until: 19-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/ Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria...

CME credits: 0.25 Valid until: 18-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/engaging-your-patient-shared-decision-making-in-hf-with-lvef40/29910/ Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/looking-ahead-integrating-cdh6-targeted-therapies-into-ovarian-cancer-treatment-paradigms/37866/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targ...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-cdh6-directed-antibody-drug-conjugates/37865/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conju...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-insights-from-early-trials-of-cdh6-targeted-therapies/37669/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MOA-cdh6-targeted-antibody-drug-conjugates/37668/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-therapeutic-landscape-of-platinum-resistant-ovarian-cancer/37667/ Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-dr...

CME credits: 0.50 Valid until: 14-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-fifth-pillar-closing-the-gap-in-hfref/37615/ For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despit...

CME credits: 0.25 Valid until: 15-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-gmg-clinical-decisions-diagnosing-early-treating-smarter-and-caring-holistically-a-case-based-treatment-approach/36276/ This case-based discussion follows Maria, a 38-year-old teacher presenting with fluctuating ptosis, diplopia, and fatigue—classic but easily overlooked signs of generaliz...

CME credits: 0.25 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-mash-with-compensated-cirrhosis-a-serious-unmet-need/37646/ Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using no...

CME credits: 1.00 Valid until: 10-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-clinical-expertise-in-celmods-transforming-multiple-myeloma-treatment/35631/ This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELM...

CME credits: 1.00 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-role-for-corticosteroids-within-the-evolving-dmd-treatment-landscape/37232/ Corticosteroids remain a cornerstone in Duchenne muscular dystrophy (DMD) management, but evolving therapies demand a more nuanced approach. This case-based activity explores how to proactively monitor and man...

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this...

CME credits: 0.50 Valid until: 05-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-hidden-threat-transforming-ckd-care-across-the-diabetes-spectrum/36523/ Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2...

CME credits: 2.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-pain-to-possibilities-safe-opioid-use-and-treatment-of-patients-with-pain/56432/ This Opioid Analgesic REMS webcast provides an FDA Blueprint-aligned learning experience to support safe, compassionate pain management through thorough assessment and individualized treatment planning. Also covere...

CME credits: 1.00 Valid until: 30-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-prioritizing-weight-loss-to-improve-osa-management/48715/ On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strategies for prioritizing weight loss to improve OSA management among select patients. =

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-Applications-in-Multidisciplinary-Care-for-Endometrial-Cancer/39298/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testin...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Applications-in-Multidisciplinary-Care-for-Cervical-Cancer/39297/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clini...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Managing-Immune-Related-Adverse-Events-in-Cervical-and-Endometrial-Cancer/39296/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-Treatment-Strategies-for-Endometrial-Cancer-After-Disease-Progression-and-Interdisciplinary-Collaboration/39295/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and perso...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-Base-for-First-Line-Treatment-Strategies-for-Endometrial-Cancer-and-Delivering-Guideline-Concordant-Care/39294/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized ca...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Role-of-Predictive-Biomarkers-in-Endometrial-Cancer/39293/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical tri...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Evidence-and-Guideline-Based-Treatment-for-Advanced-Metastatic-Cervical-Cancer/39292/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biom...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Screening-for-Cervical-Cancer/39290/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical trial evidence, and the i...

CME credits: 1.00 Valid until: 31-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Interdisciplinary-Management-of-Gynecologic-Cancers/39286/ This series features interdisciplinary discussions on the evolving management of cervical and endometrial cancers, emphasizing biomarker-driven decision-making and personalized care. Experts examine screening, biomarker testing, clinical tri...